Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅲ, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Study of TJO-087 for Evaluating 32 Weeks Safety and Efficacy in Moderate to Severe Dry Eye Disease Patients

NCT05245604 is registered in ClinicalTrials.gov with Taejoon Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05245604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅲ, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Study of TJO-087 for Evaluating 32 Weeks Safety and Efficacy in Moderate to Severe Dry Eye Disease Patients
Lead sponsor
Taejoon Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
June 19, 2020
Completion date
April 30, 2023
Enrollment
182 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye syndrome